Iga Glomerulonephritis (IGAN)

Categories: Immune diseases, Liver diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Iga Glomerulonephritis

MalaCards integrated aliases for Iga Glomerulonephritis:

Name: Iga Glomerulonephritis 12 15 17 71
Iga Nephropathy 12 74 52 15
Glomerulonephritis, Iga 52 43
Primary Immunoglobulin a Nephropathy 71
Berger's Iga or Igg Nephropathy 12
Segmental Glomerulonephritis 12
Focal Glomerulonephritis 12
Glomerulonephritis Focal 54
Primary Iga Nephropathy 12
Nephritis, Iga Type 52
Berger's Disease 52
Berger Disease 52
Igan 52


External Ids:

Disease Ontology 12 DOID:2986
MeSH 43 D005922
SNOMED-CT 67 68779003
UMLS 71 C0017661 C3161650

Summaries for Iga Glomerulonephritis

NIH Rare Diseases : 52 IgA nephropathy is a kidney disorder that occurs when IgA (immunoglobulin A), a protein that helps the body fight infections, settles in the kidneys. IgA nephropathy can occur at any age, even in childhood. After many years, deposits of IgA may cause the kidneys to leak blood and sometimes protein in the urine. In the early stages, IgA nephropathy has no symptoms. The first sign of this condition may be blood in the urine. After 10 to 20 years, the kidneys may show signs of damage and 20-40% of adults develop end-stage kidney disease. In most instances, the cause of this condition is unknown; however, certain disorders have been linked with IgA nephropathy, such as cirrhosis of the liver , celiac disease , and HIV infection . Although IgA nephropathy usually occurs in a family with no other affected members, several cases of familial IgA nephropathy have been reported. Familial IgA nephropathy is suspected to run through families in an autosomal dominant manner and is linked to genetic material on the long arm of chromosome 6 (6q22-23). There is no cure for this condition. Treatment focuses on slowing the disease and preventing complications.

MalaCards based summary : Iga Glomerulonephritis, also known as iga nephropathy, is related to iga nephropathy 1 and glomerulonephritis. An important gene associated with Iga Glomerulonephritis is CD79A (CD79a Molecule), and among its related pathways/superpathways are Staphylococcus aureus infection and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and t cells, and related phenotypes are immune system and renal/urinary system

Disease Ontology : 12 A glomerulonephritis characterized by build up of IgA antibody in the glomerulus.

Wikipedia : 74 IgA nephropathy (IgAN), also known Berger's disease (/b??r'?e?/) (and variations), or synpharyngitic... more...

Related Diseases for Iga Glomerulonephritis

Diseases related to Iga Glomerulonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 670)
# Related Disease Score Top Affiliating Genes
1 iga nephropathy 1 32.7 NPHS1 MASP1 FCAR CD79A C1GALT1 AGTR1
2 glomerulonephritis 31.4 NPHS1 MBL2 MASP1 CD79A CD40LG ALB
3 purpura 31.3 CD79A CD40LG ACE
4 immune-complex glomerulonephritis 31.2 CFHR2 CD40LG ALB
5 acute kidney tubular necrosis 31.2 REN CD40LG ALB ACE
6 polycystic kidney disease 31.1 REN ALB AGTR1 ACE
7 celiac disease 1 31.1 CD79A CD40LG CCR6 ALB
8 chlamydia 31.0 MBL2 CD79A CD40LG
9 renal hypertension 31.0 REN NPHS1 ALB AGTR1 ACE
10 pyelonephritis 31.0 MBL2 ALB ACE
11 vasculitis 30.9 PTX3 MBL2 CD79A CD40LG
12 immune deficiency disease 30.9 MBL2 CFHR2 CD79A CD40LG CCR6
13 eclampsia 30.9 REN ALB AGTR1 ACE
14 autosomal dominant polycystic kidney disease 30.9 REN ALB AGTR1 ACE
15 pre-eclampsia 30.9 REN CD40LG ALB AGTR1 ACE
16 membranoproliferative glomerulonephritis 30.8 NPHS1 CFHR2 CD79A ALB
17 c1q nephropathy 30.8 CD79A CD40LG
18 otitis media 30.8 MBL2 CD79A CD40LG ALB
19 acute cystitis 30.8 REN CD40LG CCR6 ALB ACE
20 hemolytic uremic syndrome, atypical 1 30.8 MBL2 MASP1 CFHR2
21 typhoid fever 30.8 CD40LG CCR6 ALB
22 hypertensive nephropathy 30.7 ALB AGTR1 ACE
23 chickenpox 30.7 CD40LG CCR6 ALB
24 portal hypertension 30.7 CD40LG ALB AGTR1 ACE
25 acquired immunodeficiency syndrome 30.7 CD79A CD40LG CCR6 ALB
26 spondyloarthropathy 1 30.7 FCAR CD40LG CCR6
27 end stage renal failure 30.7 REN NPHS1 CFHR2 ALB AGTR1 ACE
28 kidney disease 30.7 REN NPHS1 CD79A ALB AGTR1 ACE
29 idiopathic nephrotic syndrome 30.7 ALB ACE
30 immunoglobulin g deficiency 30.7 MBL2 CD79A CD40LG
31 malignant hypertension 30.7 REN CFHR2 AGTR1 ACE
32 vascular disease 30.7 REN PF4 CD40LG ALB ACE
33 henoch-schoenlein purpura 30.7 CFHR2 CD79A CD40LG
34 nephrosclerosis 30.7 NPHS1 AGTR1 ACE
35 pustulosis palmaris et plantaris 30.6 CD79A CD40LG CCR6
36 arteriolosclerosis 30.6 REN CD79A ALB
37 exanthem 30.6 CD40LG CCR6 ALB ACE
38 respiratory failure 30.6 REN PTX3 PF4 ALB ACE
39 complement component 3 deficiency 30.6 MBL2 MASP1 CFHR2
40 pleural empyema 30.6 CD79A CD40LG ALB
41 sleep apnea 30.6 REN ALB ACE
42 pulmonary edema 30.6 REN AGTR1 ACE
43 thrombocytopenia due to platelet alloimmunization 30.6 PF4 CD40LG CCR6
44 guillain-barre syndrome 30.6 CD79A CD40LG ALB
45 focal segmental glomerulosclerosis 30.6 NPHS1 ALB AGTR1 ACE
46 monoclonal gammopathy of uncertain significance 30.5 CFHR2 CD40LG CCR6
47 chronic graft versus host disease 30.5 CD79A ALB
48 pneumocystosis 30.5 CD40LG CCR6 ALB
49 anti-basement membrane glomerulonephritis 30.5 CFHR2 CCR6 ALB
50 cardiac tamponade 30.5 REN ALB ACE

Graphical network of the top 20 diseases related to Iga Glomerulonephritis:

Diseases related to Iga Glomerulonephritis

Symptoms & Phenotypes for Iga Glomerulonephritis

MGI Mouse Phenotypes related to Iga Glomerulonephritis:

# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.7 ACE AGTR1 ALB C1GALT1 CCR6 CD40LG
2 renal/urinary system MP:0005367 9.28 ACE AGTR1 ALB C1GALT1 CD40LG CD79A

Drugs & Therapeutics for Iga Glomerulonephritis

Drugs for Iga Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 142)
# Name Status Phase Clinical Trials Cas Number PubChem Id
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Hydroxychloroquine Approved Phase 4 118-42-3 3652
Mycophenolic acid Approved Phase 4 24280-93-1 446541
Probucol Approved, Investigational Phase 4 23288-49-5 4912
Enalaprilat Approved Phase 4 76420-72-9 6917719
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
rituximab Approved Phase 4 174722-31-7 10201696
Ramipril Approved Phase 4 87333-19-5 5362129
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
Basiliximab Approved, Investigational Phase 4 179045-86-4, 152923-56-3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
Azathioprine Approved Phase 4 446-86-6 2265
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
21 interferons Phase 4
22 Interferon-alpha Phase 4
23 Mitogens Phase 4
24 Cassava Phase 4
25 Anti-Infective Agents Phase 4
26 Antitubercular Agents Phase 4
27 Antibiotics, Antitubercular Phase 4
28 Anti-Bacterial Agents Phase 4
29 Tripterygium Phase 4
protease inhibitors Phase 4
31 HIV Protease Inhibitors Phase 4
32 Angiotensin-Converting Enzyme Inhibitors Phase 4
33 Hypolipidemic Agents Phase 4
34 Anticholesteremic Agents Phase 4
35 Antioxidants Phase 4
36 Lipid Regulating Agents Phase 4
37 Antimetabolites Phase 4
38 Vasoconstrictor Agents Phase 4
39 Antineoplastic Agents, Immunological Phase 4
40 Omega 3 Fatty Acid Phase 4
41 Proteasome Inhibitors Phase 4
42 Serine Proteinase Inhibitors Phase 4
43 Antirheumatic Agents Phase 4
44 Histamine H1 Antagonists Phase 4
45 Histamine Antagonists Phase 4
46 Alkylating Agents Phase 4
47 Immunosuppressive Agents Phase 4
48 Anti-Inflammatory Agents Phase 4
49 glucocorticoids Phase 4
50 Antineoplastic Agents, Hormonal Phase 4

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study Unknown status NCT02765594 Phase 4 Hydroxychloroquine Sulfate;Valsartan
2 A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
3 A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy Unknown status NCT01758120 Phase 4 prednisone plus cyclophosphamide;Prednisone alone
4 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4 aliskiren
5 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
6 Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
7 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
8 A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed NCT00426348 Phase 4 Valsartan;Probucol;Placebo
9 Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study Completed NCT00922311 Phase 4 Aliskiren
10 Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease Completed NCT02351752 Phase 4 Hydroxychloroquine Sulfate
11 Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy Completed NCT00367562 Phase 4 ENALAPRIL VALSARTAN METHYLPREDNISONE
12 Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. Completed NCT00755859 Phase 4 steroids plus azathioprine;steroids
13 The Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A Nephropathy Completed NCT00319761 Phase 4 Calcitriol
14 A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade Completed NCT00863252 Phase 4 mycophenolate mofetil;angiotensin blockade
15 Velcade Therapy for Severe IgA Nephropathy Completed NCT01103778 Phase 4 Bortezomib (Velcade®)
16 Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis Completed NCT01115426 Phase 4 Ramipril or losartan
17 A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy Completed NCT00498368 Phase 4 Intravenous Rituximab;ACE/ARB
18 The Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
19 To Compare the Efficacy and Safety of TW vs Valsartan in the MN Completed NCT00518219 Phase 4 TW
20 Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Active, not recruiting NCT02523768 Phase 4 ATG-F;Simulect
21 An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy Active, not recruiting NCT03218852 Phase 4 prednisone and cyclophosphamide;prednisone alone
22 Effect of Immunosuppression in IgA Nephropathy Not yet recruiting NCT03468972 Phase 4 Immunosuppressive treatment
23 A Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal Insufficiency Not yet recruiting NCT04020328 Phase 4 Leflunomide 20 mg+prednisone 0.5mg/kg/d
24 Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
25 Impact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range Proteinuria Withdrawn NCT02382523 Phase 4 Acthar 80 unit injection
26 Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f Unknown status NCT02187900 Phase 3 Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Mycophenolate mofetil (MMF)
27 Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy —— A Prospective, Randomized, Controlled, Multi-Center Clinical Trial Unknown status NCT02662283 Phase 2, Phase 3 Prednisolone;Reh-acteoside
28 A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Completed NCT02062684 Phase 2, Phase 3 Blisibimod;Placebo
29 Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy Completed NCT00554502 Phase 3 supportive therapy with: ACE-inhibitor / ARB / Statin;supportive and immunosuppressive therapy
30 An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression Completed NCT02282930 Phase 3 ACTH (Acthar) Gel
31 A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) Completed NCT00657059 Phase 3 irbesartan;methylprednisolone (MP) or prednisone (pred);mycophenolate mofetil (MMF)
32 A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy Completed NCT02232776 Phase 3 Losartan
33 Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy Completed NCT00549692 Phase 3 Omega-3 fatty acid ethylester90
34 Treatment of Early Immunoglobulin A Nephropathy by Angiotensin Converting Enzyme Inhibitor - A Randomized Controlled Trial Completed NCT01225445 Phase 3 Ramipril
35 The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study Completed NCT00870493 Phase 3 Aliskiren;Placebo
36 Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter Trial Completed NCT01392833 Phase 3 methylprednisolone;azathioprine;prednisone
37 Treatment of Early Immunoglobulin A Nephropathy by ACE Inhibitor - a Randomized Controlled Trial Completed NCT00437463 Phase 3 Ramipril
38 A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS) Completed NCT00404833 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and chlorambucil
39 A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd) Recruiting NCT03643965 Phase 3 Nefecon;Placebo oral capsule
40 Treatment of IgA Nephropathy According to Renal Lesions Recruiting NCT03188887 Phase 3 corticotherapy;Renin Angiotensin system (RAS) blockade
41 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN) Recruiting NCT03608033 Phase 3
42 Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in Patients of IgA Nephropathy With High-risk of ESRD Recruiting NCT03418779 Phase 2, Phase 3 The Yi-Qi-Qing-Jie Herbal Compound;Immunosuppressive Agents
43 A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy Recruiting NCT03762850 Phase 3 sparsentan;irbesartan
44 Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study) Enrolling by invitation NCT02647255 Phase 2, Phase 3 Methylprednisolone pulse
45 A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients Not yet recruiting NCT03357653 Phase 3 Losartan group;Placebo group
46 A Randomized Controlled Trial of Mycophenolate Mofetil in Patients With IgA Nephropathy Terminated NCT00318474 Phase 3 Mycophenolate Mofetil (MMF);MMF Placebo;ACEi;FOS
47 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Withdrawn NCT02052219 Phase 3 Blisibimod;Placebo
48 Paricalcitol for the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study Withdrawn NCT00599963 Phase 3 paricalcitol
49 Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial. Unknown status NCT02160132 Phase 2 Methylprednisolone(intravenously in the 1st-2nd-3rd month );Methylprednisolone(intravenously in the 1st-3rd-5th month)
50 A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease Unknown status NCT02682407 Phase 2

Search NIH Clinical Center for Iga Glomerulonephritis

Cochrane evidence based reviews: glomerulonephritis, iga

Genetic Tests for Iga Glomerulonephritis

Anatomical Context for Iga Glomerulonephritis

MalaCards organs/tissues related to Iga Glomerulonephritis:

Kidney, Liver, T Cells, B Cells, Tonsil, Heart, Skin

Publications for Iga Glomerulonephritis

Articles related to Iga Glomerulonephritis:

(show top 50) (show all 6671)
# Title Authors PMID Year
Glomerular deposition of mannose-binding lectin in human glomerulonephritis. 54 61
10328463 1999
Hypercholesterolemia and glomerular diseases in urinary screening of school children. 54 61
10228998 1999
Expression of PDGF and PDGF receptor mRNA in glomeruli in IgA nephropathy. 54 61
9176853 1997
Serum carnitine concentrations in different glomerular diseases with normal renal function. 54 61
8699613 1996
Steroid therapy in children with IgA nephropathy. 61
30778826 2020
Identification of susceptibility locus shared by IgA nephropathy and inflammatory bowel disease in a Chinese Han population. 61
31857673 2020
Correlation of urine protein/creatinine ratios to 24-h urinary protein for quantitating proteinuria in children. 61
31813022 2020
The Urinary Angiotensinogen to Urinary Albumin Ratio Reflects Whether the Renin-angiotensin System in the Kidney Is Activated due to Filtration of Plasma Angiotensinogen through the Damaged Glomeruli or the Production of Angiotensinogen in the Proximal Tubules. 61
31534091 2020
The therapeutic effect of dendritic cells expressing indoleamine 2,3-dioxygenase (IDO) on an IgA nephropathy mouse model. 61
31894556 2020
IgA Nephropathy After Renal Transplant: Recurrences and De Novo Cases. 61
32037064 2020
Anaphylatoxins enhance Th9 cell recruitment via the CCL20-CCR6 axis in IgA nephropathy. 61
32036611 2020
TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. 61
31748116 2020
Homocysteine and IgA nephropathy: observational and Mendelian randomization analyses. 61
31929371 2020
The role of hypertriglyceridemia and treatment patterns in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis. 61
31953719 2020
Increased Non-switched Memory B Cells are Associated with Plasmablasts, Serum IL-6 Levels and Renal Functional Impairments in IgAN Patients. 61
31670996 2020
BAFF is involved in the pathogenesis of IgA nephropathy by activating the TRAF6/NF‑κB signaling pathway in glomerular mesangial cells. 61
31974601 2020
Case report on mesangial proliferative glomerulonephritis with multicentric Castleman's disease: Approach to the onset mechanism of immunoglobulin A nephropathy. 61
31978558 2020
The Effects of Hyperuricemia on the Prognosis of IgA Nephropathy are More Potent in Females. 61
31936416 2020
Clinical relevance of membrane attack complex deposition in children with IgA nephropathy and Henoch-Schönlein purpura. 61
31932958 2020
Genetic polymorphism in C3 is associated with progression in chronic kidney disease (CKD) patients with IgA nephropathy but not in other causes of CKD. 61
32004338 2020
Crescentic IgA nephropathy in children. 61
31993782 2020
Effect of physical activity on depression symptoms in patients with IgA nephropathy. 61
31948307 2020
Effect of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator (SPPARMα), on urinary protein excretion in IgA nephropathy with hypertriglyceridemia. 61
31950425 2020
Spectrum of biopsy-proven renal disease in northern India: A single-centre study. 61
30834630 2020
Dihydroartemisinin inhibits the proliferation of IgAN mesangial cells through the mTOR signaling pathway. 61
31931362 2020
Association analysis of DNA methyltransferases in IgA nephropathy. 61
31931367 2020
An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression. 61
31922061 2020
An Exome Sequencing Study of 10 Families with IgA Nephropathy. 61
31865346 2020
Extrahepatic manifestations of hepatitis E virus: An overview. 61
31601068 2020
Flare of IGA glomerulonephritis under G-CSF stimulation regimen for autologous stem cell transplantation in systemic sclerosis. 61
31953944 2020
Association of glomerular DNA damage and DNA methylation with one-year eGFR decline in IgA nephropathy. 61
31937846 2020
Long-term blood pressure behavior and progression to end-stage renal disease in patients with immunoglobulin A nephropathy: a single-center observational study in Italy. 61
31977575 2020
Quantitative analysis of protein crotonylation identifies its association with immunoglobulin A nephropathy. 61
32016442 2020
Identification of children with chronic kidney disease through school urinary screening using urinary protein/creatinine ratio measurement: an observational study. 61
32006130 2020
Variation in complement factor H affects complement activation in immunoglobulin A vasculitis with nephritis. 61
30838755 2020
Analysis of O-glycoforms of the IgA1 hinge region by sequential deglycosylation. 61
31959827 2020
Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial. 61
31907076 2020
Increased frequency of PD-1hiCXCR5- T cells and B cells in patients with newly diagnosed IgA nephropathy. 61
31949193 2020
Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria. 61
31768803 2020
IgA1 deposition may induce NLRP3 expression and macrophage transdifferentiation of podocyte in IgA nephropathy. 61
31796125 2019
Identification of a novel COL4A5 mutation in the proband initially diagnosed as IgAN from a Chinese family with X-linked Alport syndrome. 61
31209800 2019
Specific strains of Streptococcus mutans, a pathogen of dental caries, in the tonsils, are associated with IgA nephropathy. 61
31882880 2019
Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma: A Case Report. 61
31813918 2019
Soluble fms-Like Tyrosine Kinase 1 Localization in Renal Biopsies of CKD. 61
31844810 2019
A clinicopathological comparison between IgA nephropathy and Henoch-Schönlein purpura nephritis in children: use of the Oxford classification. 61
31468231 2019
Prognostic value of connective tissue growth factor and c-Myb expression in IgA nephropathy and Henoch-Schönlein purpura-A pilot immunohistochemical study. 61
31870504 2019
The Role of IgA in the Pathogenesis of IgA Nephropathy. 61
31818032 2019
Baseline High Blood Pressure is Associated with Clinico-Pathologic Findings and Later Renal Progression in Chronic Glomerulonephritis. 61
31969924 2019
TGF-β1 inhibits the autophagy of podocytes by activating mTORC1 in IgA nephropathy. 61
31600491 2019
Alemtuzumab Induction and Steroid Minimization in IgA Nephropathy: A Matched-Cohort Analysis. 61
31875465 2019

Variations for Iga Glomerulonephritis

Expression for Iga Glomerulonephritis

Search GEO for disease gene expression data for Iga Glomerulonephritis.

Pathways for Iga Glomerulonephritis

Pathways related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.31 MBL2 MASP1 FCAR
Show member pathways
3 10.64 REN AGTR1 ACE

GO Terms for Iga Glomerulonephritis

Cellular components related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 REN PTX3 PLA2R1 PF4 MBL2 MASP1
2 extracellular space GO:0005615 9.32 REN PTX3 PF4 MIR30A MIR148B MBL2

Biological processes related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 angiotensin maturation GO:0002003 9.43 REN ACE
2 opsonization GO:0008228 9.4 PTX3 MBL2
3 complement activation, lectin pathway GO:0001867 9.37 MBL2 MASP1
4 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.32 AGTR1 ACE
5 killing by host of symbiont cells GO:0051873 9.26 PF4 MBL2
6 renin-angiotensin regulation of aldosterone production GO:0002018 9.16 REN AGTR1
7 O-glycan processing, core 1 GO:0016267 8.96 C1GALT1C1 C1GALT1
8 kidney development GO:0001822 8.92 REN C1GALT1 AGTR1 ACE

Molecular functions related to Iga Glomerulonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase activity GO:0016263 8.96 C1GALT1C1 C1GALT1
2 bradykinin receptor binding GO:0031711 8.62 AGTR1 ACE

Sources for Iga Glomerulonephritis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....